Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130316174833im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
The primary purpose of this study is to assess the rate of early discontinuation from randomized Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) for any reason other than confirmation of the negative HIV infection status of the index person in patients receiving HIV PEP for at least 28 and a maximum of 30 days.
Condition | Intervention | Phase |
---|---|---|
Human Immunodeficiency Virus (HIV) |
Drug: Darunavir/Ritonavir (DRV/r) Drug: Lopinavir in fixed combination with Ritonavir Drug: Zidovudine Drug: Tenofovir Drug: Efavirenz |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | HIV Postexposure Prophylaxis With Darunavir/r (PEPDar) |
- Number of patients with early discontinuation from randomized human immunodeficiency virus postexposure prophylaxis (HIV PEP) [ Time Frame: Up to 30 days ] [ Designated as safety issue: Yes ]Number of patients with early discontinuation from randomized HIV PEP for any reason other than confirmation of the negative HIV infection status of the index person in subjects receiving HIV PEP for at least 28 days and a maximum of 30 days.
- Number of patients with Adverse Events as a Measure of tolerability and safety of HIV PEP [ Time Frame: Up to Month 3 ] [ Designated as safety issue: Yes ]Tolerability and safety of HIV PEP.
- Changes from baseline in Patient reported outcome questionaire [ Time Frame: Baseline to Month 3 ] [ Designated as safety issue: No ]Patient reported outcome (PRO) assessment of functional impairment in conjunction with HIV PEP in 3 inter-related domains (work, social life, and family life), as calculated from subject responses to the Sheehan Disability Scale (SDS) questionnaire.
- Percentage of patients who developed detectable HIV antibodies [ Time Frame: At Month 3 ] [ Designated as safety issue: No ]Seroconversion rate of HIV antibodies while receiving HIV PEP will be evaluated as the percentage of patients who developed detectable HIV antibodies.
Estimated Enrollment: | 318 |
Study Start Date: | November 2011 |
Estimated Study Completion Date: | August 2013 |
Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: DRV/r with 2 NRTIs
DRV/r 800/100 mg q.d. with 2 NRTIs: darunavir (800 mg) in combination with low-dose ritonavir (100 mg) administered once a day for at least 28 days and a maximum of 30 days along with 2 nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs).
|
Drug: Darunavir/Ritonavir (DRV/r)
Darunavir (DRV) type=exact number, unit=mg, number=800, form=tablet, route=oral use. Tablet is taken once a day, for 28 days; Ritonavir (r) type=exact number, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
Other Name: Darunavir/Ritonavir (DRV/r)
|
Active Comparator: Comparator standard of care HIV PEP
Comparator standard of care HIV PEP (as per German-Austrian Guidelines): Administration of the standard of care HIV PEP (postexposure prophylaxis) consisting of 2 NRTIs plus third partner.
|
Drug: Lopinavir in fixed combination with Ritonavir
type=exact number, unit=mg, number=400/100, form=tablet, route=oral use. Tablet is taken once or twice a day, for at least 28 days and a maximum of 30 days.
Other Name: Lopinavir in fixed combination with Ritonavir
Drug: Zidovudine
type=exact number, unit=mg, number=250, form=tablet, route=oral use. Tablet is taken twice a day, for at least 28 days and a maximum of 30 days.
Other Name: Zidovudine
Drug: Tenofovir
type=exact number, unit=mg, number=300, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
Other Name: Tenofovir
Drug: Efavirenz
type=exact number, unit=mg, number=600, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
Other Name: Efavirenz
|
Detailed Description:
This is a randomized (study medication assigned by chance), open-label (all people involved know the identity of the intervention), active-controlled (patients are assigned to either a recognized effective treatment or the study medication), parallel-group (each treatment group will be treated at the same time), multicenter study comparing DRV/r PEP (DRV/r administered with 2 NRTIs selected at the discretion of the investigator) to standard of care PEP (as per German-Austrian guidelines) in patients at risk of HIV infection due to HIV exposure through occupational injury and non-occupational exposure. This study consists of screening period, treatment period and a follow up period. HIV PEP will be administered for a total of at least 28 days and maximum of 30 days during treatment period, including any prestudy HIV PEP initiated before screening. Approximately 318 patients will be screened and enrolled to ensure that at least 131 patients are randomly assigned to receive DRV/r PEP or standard of care PEP. Safety will be evaluated during the entire study period. Data relating to a patient's functional impairment in conjunction with HIV PEP will be collected on Day 1 as baseline data, and further on Days 14 and 28 as well as at Month 3.
![](https://webarchive.library.unt.edu/web/20130316174833im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Occupational injury and non-occupational exposure with documented human immunodeficiency virus (HIV) exposure, or potential for HIV exposure
- Indication for HIV postexposure prophylaxis (PEP), as determined by the treating physician and/or the investigator
- Women must be: postmenopausal (for at least 2 years), surgically sterile, using oral contraceptives
- Willing to continue HIV PEP for 28 days
Exclusion Criteria:
- Positive HIV rapid test
- History of liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastro intestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- Pregnant or breast-feeding
- Any condition that, in the opinion of the investigator, would compromise the well-being of the participant or the study or prevent the participant from meeting or performing study requirements
![](https://webarchive.library.unt.edu/web/20130316174833im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Contact: Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions: | JNJ.CT@sylogent.com |
Germany | |
Recruiting | |
Berlin, Germany | |
Recruiting | |
Bonn, Germany | |
Recruiting | |
Dortmund, Germany | |
Recruiting | |
Dresden, Germany | |
Withdrawn | |
Düsseldorf, Germany | |
Recruiting | |
Erlangen, Germany | |
Recruiting | |
Frankfurt, Germany | |
Recruiting | |
Freiburg, Germany | |
Recruiting | |
Hamburg, Germany | |
Withdrawn | |
Hannover, Germany | |
Not yet recruiting | |
Heidelberg, Germany | |
Withdrawn | |
Kiel, Germany | |
Recruiting | |
Köln, Germany | |
Recruiting | |
Magdeburg, Germany | |
Recruiting | |
Mainz, Germany | |
Recruiting | |
Mannheim, Germany | |
Recruiting | |
München, Germany | |
Recruiting | |
Regensburg, Germany | |
Recruiting | |
Stuttgart, Germany | |
Recruiting | |
Ulm, Germany |
Study Director: | Janssen-Cilag G.m.b.H, Germany Clinical Trial | Janssen-Cilag G.m.b.H |
![](https://webarchive.library.unt.edu/web/20130316174833im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Additional Information:
No publications provided
Responsible Party: | Janssen-Cilag G.m.b.H |
ClinicalTrials.gov Identifier: | NCT01516970 History of Changes |
Other Study ID Numbers: | CR018349, TMC114IDF3004, 2011-001303-13 |
Study First Received: | October 11, 2011 |
Last Updated: | February 21, 2013 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices Germany: Ethics Commission |
Keywords provided by Janssen-Cilag G.m.b.H:
Human Immunodeficiency Virus (HIV) Post exposure prophylaxis DRV/r Occupational injury |
Non-occupational exposure Prezista Darunavir/r |
Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome HIV Infections Immunologic Deficiency Syndromes Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Immune System Diseases Zidovudine Tenofovir Tenofovir disoproxil Efavirenz |
Ritonavir Lopinavir Darunavir Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Therapeutic Uses Anti-HIV Agents HIV Protease Inhibitors |
ClinicalTrials.gov processed this record on March 14, 2013